triazoles has been researched along with Cholangitis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bacon, BR; Bernstein, DE; Boudes, PF; Bowlus, CL; Buggisch, P; Chera, H; Choi, YJ; Clark, V; Corless, L; Doerffel, Y; Freilich, BL; Galambos, MR; Gitlin, N; Gordon, SC; Hartleb, M; Hartmann, H; Hirschfield, GM; Janczewska, E; Jonas, ME; Jones, D; Kremer, AE; Levy, C; Martin, R; McWherter, CA; Mells, GF; Odin, JA; Rochling, F; Shah, H; Sheridan, D; Shiffman, ML; Smith, JH; Steinberg, A; Swain, MG; Varga, M; Vierling, JM; Wörns, MA | 1 |
1 trial(s) available for triazoles and Cholangitis
| Article | Year |
|---|---|
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
Topics: Acetates; Adult; Aged; Alanine Transaminase; Cholangitis; Diarrhea; Double-Blind Method; Drug Administration Schedule; Female; Humans; Liver; Male; Middle Aged; Nausea; PPAR delta; Pruritus; Treatment Outcome; Triazoles; Ursodeoxycholic Acid | 2017 |